Liver specific overexpression of platelet‐derived growth factor‐B accelerates liver cancer development in chemically induced liver carcinogenesis

A genetic basis of hepatocellular carcinoma (HCC) has been well‐established and major signaling pathways, such as p53, Wnt‐signaling, transforming growth factor‐β (TGF‐β) and Ras pathways, have been identified to be essential to HCC development. Lately, the family of platelet‐derived growth factors (PDGFs) has shifted to the center of interest. We have reported on spontaneously developing liver fibrosis in PDGF‐B transgenic mice. Since HCC rarely occurs in healthy liver, but dramatically increases at the cirrhosis stage of which liver fibrosis is a preliminary stage, we investigated liver cancer development in chemically induced liver carcinogenesis in these mice. HCC induction was performed by treatment of the mice with diethylnitrosamine and phenobarbital. At an age of 6 months, the tumor development of these animals was analyzed. Not only the development of dysplastic lesions in PDGF‐B transgenic mice was significantly increased but also their malignant transformation to HCC. Furthermore, we were able to establish a key role of PDGF‐B signaling at diverse stages of liver cancer development. Here, we show that development of liver fibrosis is likely through upregulation of TGF‐β receptors by PDGF‐B. Additionally, overexpression of PDGF‐B also leads to an increased expression of β‐catenin as well as vascular endothelial growth factor and platelet endothelial cell adhesion molecule‐1 (PECAM‐1/CD31), all factors with established roles in carcinogenesis. We were able to extend the understanding of key genetic regulators in HCC development by PDGF‐B and decode essential downstream signals.

[1]  Xuri Li,et al.  Novel PDGF family members: PDGF-C and PDGF-D. , 2003, Cytokine & growth factor reviews.

[2]  Jeanne M Clark,et al.  The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.

[3]  P. Schirmacher,et al.  Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. , 2006, Journal of hepatology.

[4]  P. Bioulac-Sage,et al.  [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[5]  P. Anthony Hepatocellular carcinoma: an overview , 2001, Histopathology.

[6]  A. Gressner,et al.  Pro-fibrogenic potential of PDGF-D in liver fibrosis. , 2007, Journal of hepatology.

[7]  David I. Smith,et al.  Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.

[8]  M. Buendia Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.

[9]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[10]  R. Dirks,et al.  Signals controlling the expression of PDGF , 2004, Molecular Biology Reports.

[11]  Xinping Tan,et al.  Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer , 2007, Molecular Cancer Therapeutics.

[12]  K. McGlynn,et al.  Epidemiology and natural history of hepatocellular carcinoma. , 2005, Best practice & research. Clinical gastroenterology.

[13]  S. Fan,et al.  β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .

[14]  C. Heldin,et al.  Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.

[15]  Wei Jiang,et al.  Wnt/beta-catenin signaling pathway as a novel cancer drug target. , 2004, Current cancer drug targets.

[16]  P. Schirmacher,et al.  Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. , 2008, Gene.

[17]  F. Huang,et al.  Platelet‐derived growth factor‐B increases colon cancer cell growth in vivo by a paracrine effect , 1995, Journal of cellular physiology.

[18]  L. Gesualdo,et al.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. , 1989, The Journal of clinical investigation.

[19]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[20]  L. Qin,et al.  Overexpression of Platelet-Derived Growth Factor Receptor α in Endothelial Cells of Hepatocellular Carcinoma Associated with High Metastatic Potential , 2005, Clinical Cancer Research.

[21]  M. Kojiro,et al.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.

[22]  H. Kantarjian,et al.  Biology of platelet-derived growth factor and its involvement in disease. , 2006, Mayo Clinic proceedings.

[23]  R. Eferl,et al.  Hepatic tumor–stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge , 2009, Oncogene.

[24]  Y. N. Park,et al.  Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules. , 2003, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  S. Fan,et al.  beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. , 2001, Cancer.

[26]  E.K. Teo,et al.  Hepatocellular Carcinoma: An Asian Perspective , 2002, Digestive Diseases.

[27]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[28]  A. Tannapfel,et al.  Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis , 2002, Virchows Archiv.

[29]  P. Newman,et al.  The Role of PECAM‐1 in Vascular Cell Biology a , 1994, Annals of the New York Academy of Sciences.

[30]  Y. N. Park,et al.  Expression of Transforming Growth Factor-β1 and Transforming Growth Factor-β Receptors in Hepatocellular Carcinoma and Dysplastic Nodules , 2003, Modern Pathology.

[31]  H. Herbst,et al.  Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. , 1996, The American journal of pathology.

[32]  You-Ming Li,et al.  Expression of platelet-derived growth factor-BB in liver tissues of patients with chronic hepatitis B. , 2004, World journal of gastroenterology.

[33]  Brygida Berse,et al.  Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.

[34]  M. Choti,et al.  Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. , 2002, Human pathology.

[35]  Jin Ding,et al.  From cell signaling to cancer therapy , 2007, Acta Pharmacologica Sinica.

[36]  K. Jones,et al.  Wnt signaling: is the party in the nucleus? , 2006, Genes & development.

[37]  M. Konstadoulakis,et al.  Strategies for the management of hepatocellular carcinoma , 2007, Nature Clinical Practice Oncology.

[38]  J. Shimazaki,et al.  Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Y. N. Park,et al.  Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. , 2000, Archives of pathology & laboratory medicine.

[40]  D. Jackson The unfolding tale of PECAM‐1 , 2003, FEBS letters.

[41]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[42]  Michael Höpfner,et al.  Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. , 2008, World journal of gastroenterology.

[43]  M. Yeh,et al.  Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  N. Gassler,et al.  Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury , 2008, Laboratory Investigation.

[45]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.